Prognostic significance of the change in glucose level in the first 24 h after acute myocardial infarction: results from the CARDINAL study

被引:149
作者
Goyal, Abhinav
Mahaffey, Kenneth W.
Garg, Jyotsna
Nicolau, Jose C.
Hochman, Judith S.
Weaver, W. Douglas
Theroux, Pierre
Oliveira, Gustavo B. F.
Todaro, Thomas G.
Mojcik, Christopher F.
Armstrong, Paul W.
Granger, Christopher B.
机构
[1] Duke Clin Res Inst, Durham, NC 27715 USA
[2] Duke Univ, Med Ctr, Durham, NC 27715 USA
[3] Univ Sao Paulo, Sch Med, Inst Heart, Sao Paulo, Brazil
[4] Columbia Univ, New York, NY USA
[5] Henry Ford Hosp, Detroit, MI 48202 USA
[6] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada
[7] Inst Dante Pazzanese Cardiol, Sao Paulo, Brazil
[8] Procter & Gamble Pharmaceut, Mason, OH USA
[9] Alexion Pharmaceut Inc, Cheshire, CT USA
[10] Univ Alberta, Edmonton, AB, Canada
关键词
acute myocardial infarction; diabetes; glucose; prognosis; hyperglycemia;
D O I
10.1093/eurheartj/ehi884
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims In acute myocardial infarction (AMI), baseline hyperglycaemia predicts adverse outcomes, but the relation between subsequent change in glucose levels and outcomes is unclear. We evaluated the prognostic significance of baseline glucose and the change in glucose in the first 24 h following AMI. Methods and results We analysed 1469 AMI patients with baseline and 24 h glucose data from the CARDINAL trial database. Baseline glucose and the 24 h change in glucose (24 h glucose level subtracted from baseline glucose) were included in multivariable models for 30- and 180-day mortality. By 30 and 180 days, respectively, 45 and 74 patients had died. In the multivariable 30-day mortality model, neither baseline glucose nor the 24 h change in glucose predicted mortality in diabetic patients (n = 250). However, in nondiabetic patients (n = 1219), higher baseline glucose predicted higher mortality [hazard ratio (HR) 1.12, 95% confidence interval (CI) 1.04-1.20, per 0.6 mmol/L increase], and a greater 24 h change in glucose predicted lower mortality (HR 0.91, 95% Cl 0.86-0.96, for every 0.6 mmol/L drop in glucose in the first 24 h) at 30 days. Baseline glucose and the 24 h change in glucose remained significant multivariable mortality predictors at 180 days in nondiabetic patients. Conclusion Both higher baseline glucose and the failure of glucose levels to decrease in the first 24 h after AMI predict higher mortality in nondiabetic patients.
引用
收藏
页码:1289 / 1297
页数:9
相关论文
共 30 条
  • [1] Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002
  • [2] Impaired glucose metabolism predicts mortality after a myocardial infarction
    Bolk, J
    van der Ploeg, T
    Cornel, JH
    Arnold, AER
    Sepers, J
    Umans, VAWM
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2001, 79 (2-3) : 207 - 214
  • [3] Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus
    Cao, JJ
    Hudson, M
    Jankowski, M
    Whitehouse, F
    Weaver, WD
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (02) : 183 - 186
  • [4] Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview
    Capes, SE
    Hunt, D
    Malmberg, K
    Gerstein, HC
    [J]. LANCET, 2000, 355 (9206) : 773 - 778
  • [5] Fava S, 1996, DIABETIC MED, V13, P80, DOI 10.1002/(SICI)1096-9136(199601)13:1<80::AID-DIA10>3.0.CO
  • [6] 2-W
  • [7] A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes
    Foo, K
    Cooper, J
    Deaner, A
    Knight, C
    Suliman, A
    Ranjadayalan, K
    Timmis, AD
    [J]. HEART, 2003, 89 (05) : 512 - 516
  • [8] Garber Alan J, 2004, Endocr Pract, V10, P77
  • [9] Genuth S, 2003, DIABETES CARE, V26, P3160
  • [10] Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction - The COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial
    Granger, CB
    Mahaffey, KW
    Weaver, WD
    Theroux, P
    Hochman, JS
    Filloon, TG
    Rollins, S
    Todaro, TG
    Nicolau, JC
    Ruzyllo, W
    Armstrong, PW
    [J]. CIRCULATION, 2003, 108 (10) : 1184 - 1190